Big thanks to CompPAC investors
CompPAC is the way APC supports members of Congress who think like you do about pharmacy compounding. And where does CompPAC get its funding? From compounders like you.
CompPAC is the way APC supports members of Congress who think like you do about pharmacy compounding. And where does CompPAC get its funding? From compounders like you.
APC staff has prepared a comparison document illuminating the differences between the new USP Chapter <797> on sterile compounding that takes effect November 1 and proposed regulation from the California Board of Pharmacy.
Five U.S. Senators have written to the FDA urging that the agency assure continued patient access to compounded hormones for patients.
Last Friday, the FDA announced that it has updated the list of bulk drug substances nominated for use under section 503A.
Did they or didn’t they? Did USP take seriously input from APC (as well as that of APhA, NCPA, and numerous other pharmacy stakeholder groups)?
Jack Korbutov says the system is already paying dividends.
The Outsourcing Facilities Association announced this week that it reached a settlement agreement with the FDA.
22 members of Congress urged FDA to “craft patient-centered policies that preserve treatment options” related to compounded hormones.
Mention this letter to your pharmacy board members and executive director.
It debuted last week.